Burjeel Holdings announced that it has partnered with OncoHelix Inc. to establish a cutting-edge laboratory in Abu Dhabi to provide advanced molecular genetics, cellular and immunological profile testing to patients in the UAE. Through this exclusive agreement, Burjeel Holdings and OncoHelix Inc. strive to bring personalised medicine to clinics and hospitals in the UAE. The agreement between Burjeel Holdings and OncoHelix was signed by John Sunil, CEO, Burjeel Holdings, and Dr. Faisal Khan, CEO, OncoHelix.

The new lab will be divided into two areas. An advanced diagnostic lab arm will focus on offering ground- breaking molecular genetics and immunological profiling tests to assist oncologists and physicians in the diagnosis, risk stratification, and tailored treatment for patients with cancer, genetic diseases, or immune disorders. The second arm will expand on Burjeel Holdings' existing translational research program and analyze cancer patients' genomic and immune signatures to develop innovative approaches for diagnosis and treatment.

Burjeel Holdings expects to commence the operation of the new laboratory by the end of this year, and it will be capable of facilitating the requirements of the region's hospitals.